Arvind Dasari, MD, MS, explains how to sequence radioligand therapy, cabozantinib, and everolimus in well-differentiated neuroendocrine tumors.
|Videos|January 7, 2014
Targeted Therapies in Bladder Cancer
Author(s)Matthew D. Galsky, MD
Matthew D. Galsky, MD, discusses targeted therapy treatments for bladder cancer.
Advertisement
Matthew D. Galsky, MD, assistant professor of medicine, Department of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, director, Genitourinary Medical Oncology, Tisch Cancer Institute at Mount Sinai Medical Center, discusses targeted therapy treatments for bladder cancer.
Clinical Pearls:
- Targeting tumor angiogenesis and HSP27 could prove to be promising approaches in the treatment of bladder cancer
- While studies that are looking at anti-angiogenic approaches in bladder cancer have shown that the majority of patients do not respond, some patients did respond
- The combination of conventional chemotherapy and anti-angiogenic drugs is difficult to give because they have some overlapping side effects
- Targeting VEGF with an antibody might be more promising in terms of the ability to deliver both drugs effectively without overlapping toxicities
- A study that is exploring gemcitabine and cisplatin with or without bevacizumab should establish a role for this class of drugs in the treatment of bladder cancer
Advertisement
Related to this article
A survey of US veterans with non-muscle invasive bladder cancer identifies barriers to treatment access, care coordination challenges, and gaps in patient education.
The perioperative regimen improved event-free and overall survival in the phase 3 VOLGA trial, offering a new option for patients with muscle-invasive bladder cancer who cannot receive or decline cisplatin.
Ravi Parikh, MD, MPP, discusses the future of oncology practice, including real-world data, patient engagement, emerging technologies, and policy priorities shaping cancer care.
Renuka Iyer, MD, discusses clear documentation for AI ambient scribes and why multidisciplinary tumor boards remain essential in neuroendocrine tumor care.
Aman Chauhan, MD, reviews DAREON-7 data on obrixtamig plus chemotherapy in DLL3-positive neuroendocrine carcinoma, including response rates by DLL3 level.
Jacob Sands, MD, of Dana-Farber Cancer Institute, discusses survival gains, durability, and safety of tarlatamab plus durvalumab in the phase 3 DeLLphi-305 trial.
Renuka Iyer, MD, explains how NCCN is digitizing its guidelines with structured data to support AI tools, prior authorization, and point-of-care access.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Durvalumab-EV Combo, Expanding MIBC Treatment Options
2
New ACS Guidelines Push for Earlier Prostate Cancer Screening
3
Survey Highlights NMIBC Care Challenges Among US Military Service, Veterans
4
Dr Dasari on Sequencing RLT, Cabozantinib, and Everolimus in NETs
5